Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Value of flow cytometry for MRD-based relapse prediction in B-cell precursor ALL in a multicenter setting

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Targeted inhibition of cooperative mutation- and therapy-induced AKT activation in AML effectively enhances response to chemotherapy

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Clinical and genetic characteristics of children with acute lymphoblastic leukemia and Li-Fraumeni syndrome

    Research output: Contribution to journalLetterResearchpeer-review

  3. Clinical impact of clonal hematopoiesis in patients with lymphoma undergoing ASCT: a national population-based cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Selection criteria for assembling a pediatric cancer predisposition syndrome gene panel

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Parenthood among men diagnosed with cancer in childhood and early adulthood: trends over time in a Danish national cohort

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Genomforskningsprojekt påviser TP53-mutation hos en pige med rabdomyosarkom

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The Need for Hospitalization due to SARS-CoV-2 in Children: A Population-based Estimate

    Research output: Contribution to journalLetterResearchpeer-review

  • S Modvig
  • H Hallböök
  • H O Madsen
  • S Siitonen
  • S Rosthøj
  • A Tierens
  • V Juvonen
  • L T N Osnes
  • H Vålerhaugen
  • M Hultdin
  • R Matuzeviciene
  • M Stoskus
  • M Marincevic
  • A Lilleorg
  • M Ehinger
  • U Norén-Nystrøm
  • N Toft
  • M Taskinen
  • O G Jónsson
  • K Pruunsild
  • G Vaitkeviciene
  • K Vettenranta
  • B Lund
  • J Abrahamsson
  • A Porwit
  • K Schmiegelow
  • H V Marquart
View graph of relations

PCR of TCR/Ig gene rearrangements is considered the method of choice for minimal residual disease (MRD) quantification in BCP-ALL, but flow cytometry analysis of leukemia-associated immunophenotypes (FCM-MRD) is faster and biologically more informative. FCM-MRD performed in 18 laboratories across seven countries was used for risk stratification of 1487 patients with BCP-ALL enrolled in the NOPHO ALL2008 protocol. When no informative FCM-marker was available, risk stratification was based on real-time quantitative PCR. An informative FCM-marker was found in 96.2% and only two patients (0.14%) had non-informative FCM and non-informative PCR-markers. The overall 5-year event-free survival was 86.1% with a cumulative incidence of relapse (CIR5y) of 9.5%. FCM-MRD levels on days 15 (HzR 4.0, p < 0.0001), 29 (HzR 2.7, p < 0.0001), and 79 (HzR 3.5, p < 0.0001) associated with hazard of relapse adjusted for age, cytogenetics, and WBC. The early (day 15) response associated with CIR5y adjusted for day 29 FCM-MRD, with higher levels in adults (median 2.4 × 10-2 versus 5.2 × 10-3, p < 0.0001). Undetectable FCM- and/or PCR-MRD on day 29 identified patients with a very good outcome (CIR5y = 3.2%). For patients who did not undergo transplantation, day 79 FCM-MRD > 10-4 associated with a CIR5y = 22.1%. In conclusion, FCM-MRD performed in a multicenter setting is a clinically useful method for MRD-based treatment stratification in BCP-ALL.

Original languageEnglish
JournalLeukemia
Volume35
Issue number7
Pages (from-to)1894-1906
Number of pages13
ISSN0887-6924
DOIs
Publication statusPublished - Jul 2021

ID: 61784243